AR073905A1 - Ligandos que tienen especificidad de union por dc-sign - Google Patents

Ligandos que tienen especificidad de union por dc-sign

Info

Publication number
AR073905A1
AR073905A1 ARP090104011A ARP090104011A AR073905A1 AR 073905 A1 AR073905 A1 AR 073905A1 AR P090104011 A ARP090104011 A AR P090104011A AR P090104011 A ARP090104011 A AR P090104011A AR 073905 A1 AR073905 A1 AR 073905A1
Authority
AR
Argentina
Prior art keywords
sign
links
compositions
immunoglobulin
union
Prior art date
Application number
ARP090104011A
Other languages
English (en)
Spanish (es)
Original Assignee
Domantis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Domantis Ltd filed Critical Domantis Ltd
Publication of AR073905A1 publication Critical patent/AR073905A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
ARP090104011A 2008-10-21 2009-10-19 Ligandos que tienen especificidad de union por dc-sign AR073905A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10708508P 2008-10-21 2008-10-21

Publications (1)

Publication Number Publication Date
AR073905A1 true AR073905A1 (es) 2010-12-09

Family

ID=42062429

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090104011A AR073905A1 (es) 2008-10-21 2009-10-19 Ligandos que tienen especificidad de union por dc-sign

Country Status (16)

Country Link
US (1) US20110257373A1 (https=)
EP (1) EP2356149A2 (https=)
JP (1) JP2012506237A (https=)
KR (1) KR20110071139A (https=)
CN (1) CN102257009A (https=)
AR (1) AR073905A1 (https=)
AU (1) AU2009306424A1 (https=)
BR (1) BRPI0919714A2 (https=)
CA (1) CA2740856A1 (https=)
EA (1) EA201100488A1 (https=)
IL (1) IL212086A0 (https=)
MX (1) MX2011004244A (https=)
TW (1) TW201019962A (https=)
UY (1) UY32189A (https=)
WO (1) WO2010046337A2 (https=)
ZA (1) ZA201102763B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010046338A1 (en) * 2008-10-21 2010-04-29 Domantis Limited Composition for targeting dendritic cells
WO2013095973A1 (en) * 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
WO2023028593A2 (en) * 2021-08-27 2023-03-02 University Of Georgia Research Foundation, Inc. Targeted nanoparticles and their uses related to infectious disease
CN118184795B (zh) * 2022-12-13 2025-03-21 成都维瑾柏鳌生物医药科技有限公司 抗hiv-1的重组蛋白及其应用
CN120591214A (zh) * 2025-07-02 2025-09-05 山东第一医科大学第二附属医院 一种过表达dc-sign基因的重组arh77细胞系及其构建方法与应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0598108A1 (en) * 1992-06-05 1994-05-25 Dade Produktions AG Rabbit single domain antibody and use thereof
CA2505316C (en) * 2002-11-08 2014-08-05 Ablynx N.V. Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1587838B1 (en) * 2003-01-10 2015-04-15 Ablynx N.V. Therapeutic polypeptides, homologues thereof, fragments thereof and their use in modulating platelet-mediated aggregation
US20090005257A1 (en) * 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
CN1845938B (zh) * 2003-06-30 2010-05-26 杜门蒂斯有限公司 多肽
DE602004025711D1 (de) * 2003-08-21 2010-04-08 Lipotek Pty Ltd In vivo targeting von dendritischen zellen
EA012622B1 (ru) * 2004-06-01 2009-10-30 Домэнтис Лимитед Биспецифичные гибридные антитела с увеличенным периодом полувыведения из сыворотки
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
CA2589800A1 (en) * 2004-12-02 2006-06-08 Domantis Limited Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
CA2601115A1 (en) * 2005-03-18 2006-09-21 Domantis Limited Antibodies against candida antigens
US20100021473A1 (en) * 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
JP2009518024A (ja) * 2005-12-06 2009-05-07 ドマンティス リミテッド Ｅｇｆｒおよび／またはｖｅｇｆに対して結合特異性を有するリガンドおよびその使用法
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
AU2007300543A1 (en) * 2006-09-26 2008-04-03 Alexion Pharmaceuticals, Inc. Compositions and methods for enhancing an adjuvant
WO2008070363A2 (en) * 2006-10-31 2008-06-12 Domantis Limited Intrabodies
CN101182539A (zh) * 2007-11-06 2008-05-21 浙江大学 Dc-sign启动子荧光素酶报告质粒的构建方法

Also Published As

Publication number Publication date
AU2009306424A1 (en) 2010-04-29
WO2010046337A2 (en) 2010-04-29
BRPI0919714A2 (pt) 2015-12-08
TW201019962A (en) 2010-06-01
KR20110071139A (ko) 2011-06-28
WO2010046337A3 (en) 2010-07-01
US20110257373A1 (en) 2011-10-20
IL212086A0 (en) 2011-06-30
CA2740856A1 (en) 2010-04-29
JP2012506237A (ja) 2012-03-15
UY32189A (es) 2010-05-31
EP2356149A2 (en) 2011-08-17
CN102257009A (zh) 2011-11-23
ZA201102763B (en) 2012-09-26
EA201100488A1 (ru) 2011-12-30
MX2011004244A (es) 2011-05-25

Similar Documents

Publication Publication Date Title
RU2014136702A (ru) Одноцепочечные антитела и другие гетеромультимеры
CO6571853A2 (es) Composiciones catalizadoras de metaloceno heteronuclear nano - enlazado y sus productos polímericos
UA114707C2 (uk) БІСПЕЦИФІЧНА ЗВ'ЯЗУВАЛЬНА МОЛЕКУЛА, ЯКА ЗВ'ЯЗУЄТЬСЯ З VEGF I Ang2
CY1121560T1 (el) Ανοσογονικη συνθεση
BR112012023015A2 (pt) imunoensaios para lenalidomida e talidomida
CY1122978T1 (el) Αντισωματα εναντι-vla-4
EA201590209A1 (ru) Применение cart19 для истощения нормальных b-клеток для индукции толерантности
CL2016001256A1 (es) Composiciones y métodos para anticuerpos dirigidos factor de p (divisional de sol. n° 1640-14).
MX372849B (es) Partículas conjugadas con péptidos.
UA112416C2 (uk) Антитіло до fap і способи його застосування
TR201820837T4 (tr) Natalizumab antikor formülasyonları.
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
EA201790175A1 (ru) Применение модифицированных t-клеток с химерными антигенными рецепторами для лечения злокачественных новообразований
AR073905A1 (es) Ligandos que tienen especificidad de union por dc-sign
UA116632C2 (uk) Химерний білок, який містить фактор viii та фактор віллебранда, і його застосування
CR9969A (es) Anticuerpos anti-globulomero ab, porciones de union a antigeno de estos, hibridomas correspondientes, acidos nucleicos, vectores, celulas huesped, metodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos
EA201491573A1 (ru) Применение передающего сигнал домена cd2 в химерных антигенспецифических рецепторах второго поколения
TN2010000169A1 (en) Molecules and methods for modulating complement component
MX2015010377A (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos.
MY159396A (en) Compositions and methods for antibodies targeting complement protein c5
BR112014019611A2 (pt) agentes de ligação mica
UY35063A (es) Composiciones y métodos que se dirigen a células estromales para el tratamiento del cáncer
AR053266A1 (es) Agentes de union
IN2014CN02906A (https=)
PE20142451A1 (es) Composiciones de conjugados de xten y metodos para realizar las mismas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal